Back to list

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: Results from the ASEAN cohort of the A1chieve study

Mary Anne Lim-Abrahan a * , Anand B. Jain b, Wan Mohamad Wan Bebakar c, Darren Seah d and Pradana Soewondo e

Diabetes Research and Clinical Practice, pages S3 - S9

Published online Aug-2013


Article view:

Abstract

Aim

To determine the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in the ASEAN cohort of the A1chieve study.

Methods

Type 2 diabetes patients from Indonesia, Malaysia, Philippines and Singapore prescribed BIAsp 30 therapy were included. The primary outcome was evaluation of serious adverse drug reactions including major hypoglycaemia over 24 weeks. Secondary outcomes were changes in hypoglycaemic events, serious adverse events (SAEs) and effectiveness parameters.

Results

This sub-analysis included 2798 patients (insulin-naive, 1903; insulin-experienced, 895) with mean age ± SD, 55.3±10.8 years, BMI, 24.9±4.6kg/m2 and diabetes duration, 7.5±5.9 years. Baseline HbA1c in the entire cohort was poor (9.9%, 85 mmol/mol). A total of 15 SAEs were reported in 7 insulin-experienced patients (1 moderate event was related to BIAsp 30). Overall hypoglycaemia at Week 24 was 0.88 events/patient-year compared to 1.71 events/patient-year reported at baseline (change in proportion of patients affected, p < 0.0001). No major hypoglycaemia was reported at Week 24. BIAsp 30 significantly improved glucose control (HbA1c, fasting plasma glucose and postprandial plasma glucose, p < 0.001) at Week 24. The proportion of patients achieving HbA1c <7.0% at Week 24 was 35.3% compared to 3.5% at baseline. The lipid profile and systolic blood pressure also improved significantly (p < 0.001). Quality of life was positively impacted (mean change in visual analogue scores from EQ-5D = 10.6±13.8 points, p < 0.001).

Conclusion

BIAsp 30 was well-tolerated and improved glucose control while decreasing the risk of hypoglycaemia.

Keywords: ASEAN, Biphasic insulin aspart 30, A1Chieve.


Article Outline

References

  • 1 International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium; 2011, updated 14 November 2012.
  • 2 S Wild, G Roglic, A Green, R Sicree, H King. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;127(5):1043-1047
  • 3 K Niswender. Early and aggressive initiation of insulin therapy for type 2 diabetes: What is the evidence?. Clin Diab. 2009;27:60-68 Crossref.
  • 4 RC Turner, CA Cull, V Frighi, RR Holman. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012 Crossref.
  • 5 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
  • 6 M Evans, PM Schumm-Draeger, J Vora, AB King. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-684 Crossref.
  • 7 JS Christiansen, JA Vaz, Z Metelko, M Bogoev, I Dedov. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(6):446-454 Crossref.
  • 8 K Hermansen, M Colombo, H Storgaard, A ØStergaard, K Kølendorf, S Madsbad. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25(5):883-888 Crossref.
  • 9 SC Gough, J Tibaldi. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review. Clin Drug Invest. 2007;27(5):299-324 Crossref.
  • 10 D Khutsoane, SK Sharma, M Almustafa, HC Jang, ST Azar, R Danciulescu, et al., PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222 Crossref.
  • 11 P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., on behalf of the IMPROVE™ Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):522-531 Crossref.
  • 12 E Paz-Pacheco. Diabetes Clinical Practice Guidelines (CPGs) for the ASEAN region: Country initiatives for collectively enhanced diabetes care in the region. JAFES. 2011;26(1):36-37 Crossref.
  • 13 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363 Abstract, Full-text, PDF, Crossref.
  • 14 CJ Currie, JR Peters, A Tynan, M Evans, RJ Heine, OL Bracco, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-489 Crossref.
  • 15 American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34(Suppl 1):S11-S61 Crossref.
  • 16 RR Rubin, M Peyrot. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205-218 Crossref.

Footnotes

a University of the Philippines College of Medicine, Manila, Philippines University of the Philippines College of Medicine, Manila, Philippines

b Novo Nordisk Pharma Malaysia Sdn Bhd, Kuala Lumpur, Malaysia Novo Nordisk Pharma Malaysia Sdn Bhd, Kuala Lumpur, Malaysia

c Universiti Sains Malaysia, Kelantan, Malaysia Universiti Sains Malaysia, Kelantan, Malaysia

d National Healthcare Group Polyclinics, Toa Payoh Polyclinic, Singapore National Healthcare Group Polyclinics, Toa Payoh Polyclinic, Singapore

e University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia

* Corresponding author at: Manila Doctors Hospital, Rm 804, 667 U.N. Ave. Ermita Manila, Philippines. Tel: +632 524 3011; loc. 5280 / +639 178 980 251

Back to list